# Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

> **NCT00361842** · PHASE2 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 65 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection

## Key facts

- **NCT ID:** NCT00361842
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00361842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00361842, "Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00361842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*